Renal protective effect of antiplatelet therapy in antiphospholipid antibody-positive lupus nephritis patients without antiphospholipid syndrome

Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa, Takahiro Okazaki, Hidehiro Yamada, Shoichi Ozaki, Kimito Kawahata

研究成果: Article

抄録

We sought to evaluate the effect of antiplatelet therapy in addition to conventional immunosuppressive therapy for lupus nephritis (LN) patients positive for antiphospholipid antibodies (aPL) without definite antiphospholipid syndrome (APS). Methods Patients with biopsy-proven LN class III or IV were retrospectively evaluated. We selected patients positive for anticardiolipin antibody (aCL) or lupus anticoagulant (LA) who did not meet the criteria for a diagnosis of APS. The patients were divided into two subgroups according to whether antiplatelet therapy was received. The cumulative complete renal response (CR) rate, relapse-free rate, and change in estimated glomerular filtration rate (eGFR) over 3 years after induction therapy were calculated. Results We identified 17 patients who received antiplatelet therapy and 21 who did not. Baseline clinicopathological characteristics and immunosuppressive therapy did not show a significant difference between the two groups except for a higher incidence of LN class IV in the treatment group (p = 0.03). There was no difference in cumulative CR rate, relapse-free rate, or eGFR change between these subgroups. However, when data on LA-positive patients were assessed, an improvement in eGFR was found (p = 0.04) in patients receiving antiplatelet treatment. Conclusion Addition of anti-platelet therapy was associated with an improvement of eGFR in LA-positive patients with LN class III or IV.

元の言語English
記事番号e0196172
ジャーナルPloS one
13
発行部数5
DOI
出版物ステータスPublished - 2018 5 1
外部発表Yes

Fingerprint

renoprotective effect
nephritis
Lupus Nephritis
Antiphospholipid Antibodies
Antiphospholipid Syndrome
Lupus Coagulation Inhibitor
Kidney
therapeutics
antibodies
glomerular filtration rate
Immunosuppressive Agents
Glomerular Filtration Rate
anticoagulants
immunosuppressive agents
Anticardiolipin Antibodies
Biopsy
relapse
Therapeutics
Platelets
kidneys

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

これを引用

Renal protective effect of antiplatelet therapy in antiphospholipid antibody-positive lupus nephritis patients without antiphospholipid syndrome. / Hanaoka, Hironari; Iida, Harunobu; Kiyokawa, Tomofumi; Takakuwa, Yukiko; Okazaki, Takahiro; Yamada, Hidehiro; Ozaki, Shoichi; Kawahata, Kimito.

:: PloS one, 巻 13, 番号 5, e0196172, 01.05.2018.

研究成果: Article

Hanaoka, Hironari ; Iida, Harunobu ; Kiyokawa, Tomofumi ; Takakuwa, Yukiko ; Okazaki, Takahiro ; Yamada, Hidehiro ; Ozaki, Shoichi ; Kawahata, Kimito. / Renal protective effect of antiplatelet therapy in antiphospholipid antibody-positive lupus nephritis patients without antiphospholipid syndrome. :: PloS one. 2018 ; 巻 13, 番号 5.
@article{2133da683b62447dac19acfd203a46f2,
title = "Renal protective effect of antiplatelet therapy in antiphospholipid antibody-positive lupus nephritis patients without antiphospholipid syndrome",
abstract = "We sought to evaluate the effect of antiplatelet therapy in addition to conventional immunosuppressive therapy for lupus nephritis (LN) patients positive for antiphospholipid antibodies (aPL) without definite antiphospholipid syndrome (APS). Methods Patients with biopsy-proven LN class III or IV were retrospectively evaluated. We selected patients positive for anticardiolipin antibody (aCL) or lupus anticoagulant (LA) who did not meet the criteria for a diagnosis of APS. The patients were divided into two subgroups according to whether antiplatelet therapy was received. The cumulative complete renal response (CR) rate, relapse-free rate, and change in estimated glomerular filtration rate (eGFR) over 3 years after induction therapy were calculated. Results We identified 17 patients who received antiplatelet therapy and 21 who did not. Baseline clinicopathological characteristics and immunosuppressive therapy did not show a significant difference between the two groups except for a higher incidence of LN class IV in the treatment group (p = 0.03). There was no difference in cumulative CR rate, relapse-free rate, or eGFR change between these subgroups. However, when data on LA-positive patients were assessed, an improvement in eGFR was found (p = 0.04) in patients receiving antiplatelet treatment. Conclusion Addition of anti-platelet therapy was associated with an improvement of eGFR in LA-positive patients with LN class III or IV.",
author = "Hironari Hanaoka and Harunobu Iida and Tomofumi Kiyokawa and Yukiko Takakuwa and Takahiro Okazaki and Hidehiro Yamada and Shoichi Ozaki and Kimito Kawahata",
year = "2018",
month = "5",
day = "1",
doi = "10.1371/journal.pone.0196172",
language = "English",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Renal protective effect of antiplatelet therapy in antiphospholipid antibody-positive lupus nephritis patients without antiphospholipid syndrome

AU - Hanaoka, Hironari

AU - Iida, Harunobu

AU - Kiyokawa, Tomofumi

AU - Takakuwa, Yukiko

AU - Okazaki, Takahiro

AU - Yamada, Hidehiro

AU - Ozaki, Shoichi

AU - Kawahata, Kimito

PY - 2018/5/1

Y1 - 2018/5/1

N2 - We sought to evaluate the effect of antiplatelet therapy in addition to conventional immunosuppressive therapy for lupus nephritis (LN) patients positive for antiphospholipid antibodies (aPL) without definite antiphospholipid syndrome (APS). Methods Patients with biopsy-proven LN class III or IV were retrospectively evaluated. We selected patients positive for anticardiolipin antibody (aCL) or lupus anticoagulant (LA) who did not meet the criteria for a diagnosis of APS. The patients were divided into two subgroups according to whether antiplatelet therapy was received. The cumulative complete renal response (CR) rate, relapse-free rate, and change in estimated glomerular filtration rate (eGFR) over 3 years after induction therapy were calculated. Results We identified 17 patients who received antiplatelet therapy and 21 who did not. Baseline clinicopathological characteristics and immunosuppressive therapy did not show a significant difference between the two groups except for a higher incidence of LN class IV in the treatment group (p = 0.03). There was no difference in cumulative CR rate, relapse-free rate, or eGFR change between these subgroups. However, when data on LA-positive patients were assessed, an improvement in eGFR was found (p = 0.04) in patients receiving antiplatelet treatment. Conclusion Addition of anti-platelet therapy was associated with an improvement of eGFR in LA-positive patients with LN class III or IV.

AB - We sought to evaluate the effect of antiplatelet therapy in addition to conventional immunosuppressive therapy for lupus nephritis (LN) patients positive for antiphospholipid antibodies (aPL) without definite antiphospholipid syndrome (APS). Methods Patients with biopsy-proven LN class III or IV were retrospectively evaluated. We selected patients positive for anticardiolipin antibody (aCL) or lupus anticoagulant (LA) who did not meet the criteria for a diagnosis of APS. The patients were divided into two subgroups according to whether antiplatelet therapy was received. The cumulative complete renal response (CR) rate, relapse-free rate, and change in estimated glomerular filtration rate (eGFR) over 3 years after induction therapy were calculated. Results We identified 17 patients who received antiplatelet therapy and 21 who did not. Baseline clinicopathological characteristics and immunosuppressive therapy did not show a significant difference between the two groups except for a higher incidence of LN class IV in the treatment group (p = 0.03). There was no difference in cumulative CR rate, relapse-free rate, or eGFR change between these subgroups. However, when data on LA-positive patients were assessed, an improvement in eGFR was found (p = 0.04) in patients receiving antiplatelet treatment. Conclusion Addition of anti-platelet therapy was associated with an improvement of eGFR in LA-positive patients with LN class III or IV.

UR - http://www.scopus.com/inward/record.url?scp=85046902558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046902558&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0196172

DO - 10.1371/journal.pone.0196172

M3 - Article

C2 - 29723256

AN - SCOPUS:85046902558

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e0196172

ER -